

Companion Diagnostics For Targeted Therapies Market - Strategic Insights and Forecasts (2026-2031)

<https://marketpublishers.com/r/C9DED1CB5583EN.html>

Date: April 2026

Pages: 156

Price: US\$ 3,950.00 (Single User License)

ID: C9DED1CB5583EN

Abstracts

The Companion Diagnostics for Targeted Therapies market is projected to expand at a CAGR of 13.3%, attaining USD 15.1 billion in 2031 from USD 8.1 billion in 2026.

The global companion diagnostics for targeted therapies market is positioned as a critical enabler of precision medicine, supporting the identification of patient populations most likely to benefit from specific therapeutic interventions. These diagnostics play a vital role in aligning treatment strategies with individual genetic and molecular profiles, particularly in oncology and complex chronic diseases. The market is gaining momentum due to the increasing adoption of targeted therapies, rising emphasis on personalized healthcare, and the growing integration of biomarker-based testing into clinical workflows. As pharmaceutical companies increasingly co-develop drugs and diagnostics, companion diagnostics are becoming an integral component of modern drug development and commercialization strategies.

Market Drivers

A primary driver is the increasing prevalence of cancer and other chronic diseases, which require targeted and personalized treatment approaches. Companion diagnostics enable precise biomarker identification, allowing clinicians to select therapies that improve treatment outcomes and reduce adverse effects.

The growing pipeline and approval of targeted therapies is another significant factor. As more precision drugs enter the market, the need for corresponding diagnostic tools to identify eligible patients continues to rise. This parallel growth is strengthening demand for validated biomarker testing platforms.

Technological advancements in molecular diagnostics are further accelerating market expansion. Innovations in next-generation sequencing, polymerase chain reaction, and multiplex assays enable rapid and accurate detection of multiple biomarkers simultaneously. These technologies enhance scalability, diagnostic accuracy, and clinical utility.

Additionally, regulatory support for co-development models is encouraging collaboration between pharmaceutical and diagnostics companies. Streamlined approval pathways for companion diagnostics and targeted therapies are increasing industry confidence and investment in this segment.

Market Restraints

High development and validation costs remain a significant challenge. Companion diagnostic assays require extensive clinical validation alongside targeted therapies, leading to increased development timelines and financial burden.

Variability in reimbursement policies across regions also limits adoption. Inconsistent coverage for diagnostic tests creates uncertainty for healthcare providers and laboratories, affecting market penetration.

Limited access to advanced molecular testing infrastructure in developing regions further constrains growth. The lack of skilled professionals and specialized laboratory capabilities restricts widespread implementation. Standardization of testing methodologies and consistent assay performance across laboratories also remain ongoing challenges.

Technology and Segment Insights

The market is segmented by product type, technology, application, and geography. Assays, kits, and reagents represent a dominant segment due to their essential role in detecting genetic mutations and protein expressions used in targeted therapy selection.

By technology, next-generation sequencing is a key segment, enabling comprehensive genomic profiling and simultaneous analysis of multiple biomarkers. This capability is particularly important in precision oncology, where complex genetic variations must be identified accurately.

In terms of application, oncology dominates the market, driven by the widespread use of

biomarker-based testing in cancer diagnosis and treatment selection. Companion diagnostics are critical in identifying genetically altered tumors and guiding targeted therapies, improving clinical outcomes.

End-users include hospitals, diagnostic laboratories, and research institutions. Diagnostic laboratories hold a significant share due to their specialized testing capabilities and high throughput of molecular diagnostics.

Competitive and Strategic Outlook

The competitive landscape is characterized by strong participation from global diagnostics and life sciences companies focusing on innovation and strategic collaborations. Key players such as Roche Diagnostics, Thermo Fisher Scientific, Illumina, Agilent Technologies, and QIAGEN are investing in advanced molecular testing platforms and expanding their biomarker portfolios.

Strategic initiatives include partnerships between pharmaceutical and diagnostics companies for co-development of therapies and companion tests. Companies are also investing in next-generation sequencing platforms, multiplex assays, and bioinformatics tools to enhance diagnostic accuracy and scalability.

Emerging trends include the expansion of companion diagnostics beyond oncology into cardiovascular, neurological, and autoimmune diseases, as well as the integration of artificial intelligence to improve biomarker discovery and data interpretation.

Conclusion

The global companion diagnostics for targeted therapies market is expected to witness steady growth, driven by the expansion of precision medicine, increasing targeted therapy approvals, and advancements in molecular diagnostics. While high costs, regulatory complexities, and infrastructure limitations remain key challenges, ongoing innovation and collaborative development models will support long-term market expansion.

Key Benefits of this Report

Insightful Analysis: Gain detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.

Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.

Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.

Actionable Recommendations: Support strategic decisions to unlock new revenue streams.

Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2025 and forecast data from 2026 to 2031

Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis

Competitive positioning, strategies, and market share evaluation

Revenue growth and forecast assessment across segments and regions

Company profiling including strategies, products, financials, and key developments

Contents

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

- 2.1. Market Overview
- 2.2. Market Definition
- 2.3. Scope of the Study
- 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Porter's Five Forces Analysis
- 3.5. Industry Value Chain Analysis
- 3.6. Policies and Regulations
- 3.7. Strategic Recommendations
- 3.8. Product Pipeline Analysis
- 3.9. Incidence and Prevalence Analysis
- 3.10. Patent Analysis

4. TECHNOLOGICAL OUTLOOK

5. COMPANION DIAGNOSTICS FOR TARGETED THERAPIES MARKET BY COMPONENT

- 5.1. Introduction
- 5.2. Assays, Kits & Reagents
- 5.3 Instruments
- 5.4 Software & Services

6. COMPANION DIAGNOSTICS FOR TARGETED THERAPIES MARKET BY TECHNOLOGY

- 6.1. Introduction
- 6.2. Polymerase Chain Reaction (PCR)

- 6.3. Next-Generation Sequencing (NGS)
- 6.4. Immunohistochemistry (IHC)
- 6.5. In Situ Hybridization (ISH)
- 6.6. Gene Expression Profiling

7. COMPANION DIAGNOSTICS FOR TARGETED THERAPIES MARKET BY APPLICATION

- 7.1. Introduction
- 7.2. Oncology
- 7.3. Cardiology
- 7.4. Neurology
- 7.5. Infectious Diseases

8. COMPANION DIAGNOSTICS FOR TARGETED THERAPIES MARKET BY GEOGRAPHY

- 8.1. Introduction
- 8.2. North America
 - 8.2.1. USA
 - 8.2.2. Canada
 - 8.2.3. Mexico
- 8.3. South America
 - 8.3.1. Brazil
 - 8.3.2. Argentina
 - 8.3.3. Others
- 8.4. Europe
 - 8.4.1. United Kingdom
 - 8.4.2. Germany
 - 8.4.3. France
 - 8.4.4. Spain
 - 8.4.5. Others
- 8.5. Middle East and Africa
 - 8.5.1. Saudi Arabia
 - 8.5.2. UAE
 - 8.5.3. Others
- 8.6. Asia Pacific
 - 8.6.1. China
 - 8.6.2. India

- 8.6.3. Japan
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

- 8.1. Major Players and Strategy Analysis
- 8.2. Market Share Analysis
- 8.3. Mergers, Acquisitions, Agreements, and Collaborations
- 8.4. Competitive Dashboard

10. COMPANY PROFILES

- 10.1. Roche Diagnostics
- 10.2. Abbott Laboratories
- 10.3. Thermo Fisher Scientific
- 10.4. Agilent Technologies
- 10.5. Qiagen
- 10.6. Illumina
- 10.7. Danaher Corporation
- 10.8. Bio-Rad Laboratories
- 10.9. Myriad Genetics
- 10.10. Hologic

11. APPENDIX

- 11.1. Currency
- 11.2. Assumptions
- 11.3. Base and Forecast Years Timeline
- 11.4. Key benefits for the stakeholders
- 11.5. Research Methodology
- 11.6. Abbreviations

I would like to order

Product name: Companion Diagnostics For Targeted Therapies Market - Strategic Insights and Forecasts (2026-2031)

Product link: <https://marketpublishers.com/r/C9DED1CB5583EN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C9DED1CB5583EN.html>